Compare BioNano Genomics Inc (BNGO) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Petróleo Brasileiro SA — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Petróleo Brasileiro SA trades at $17.86 (market cap $112.19B). The key difference: Petróleo Brasileiro SA is far larger — about 8213× BioNano Genomics Inc's market cap, and Petróleo Brasileiro SA pays a 9.42% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | PBR | |
|---|---|---|
Market Cap | $13.66M | $112.19B |
Sector | Health | Technology |
52-Week High | $4.92 | $22.03 |
52-Week Low | $1.06 | $11.54 |
Enterprise Value | $16.26M | $172.61B |
Dividend Yield | — | 9.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
PBR trades at $17.91, down 2.29% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a low P/E of 4.53 and robust profitability with a 24.52% net income margin. Recent Q2 2026 earnings beat expectations, with net profit nearly doubling year-over-year, driven by record production and higher oil prices (Reuters, 2026-08-06).
The investment case is supported by attractive valuations and strong cash flows, but faces headwinds from technical selling pressure and regulatory uncertainty. Analyst consensus is bullish with 50% buy ratings, though near-term price action may remain volatile amid broader market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
